Back to Search
Start Over
High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
- Source :
-
The Laryngoscope [Laryngoscope] 2004 Sep; Vol. 114 (9), pp. 1660-7. - Publication Year :
- 2004
-
Abstract
- Objectives/hypothesis: Ototoxicity is a common side effect of high-dose cisplatin treatment. Thiol-containing chemoprotectors ameliorate cisplatin ototoxicity under experimental conditions. The trial was initiated to test the efficacy of amifostine protection in high-dose cisplatin treatment (125-150 mg/m) for metastatic malignant melanoma, to correlate the ototoxic outcome with cisplatin pharmacokinetics, and to evaluate the importance of using a selective analytical method for the quantification of cisplatin.<br />Study Design: Prospective study of 15 patients with stage IV malignant melanoma.<br />Methods: Clinical follow-up of therapeutic response, pure-tone audiometry, and analysis of cisplatin and its monohydrated complex in blood ultrafiltrate by liquid chromatography with postcolumn derivatization were performed. Ultrafiltered blood platinum was analyzed by inductively coupled plasma mass spectrometry.<br />Results: Ototoxicity and gastrointestinal toxicity were the most prominent side effects. Three patients ultimately required hearing aids. All patients had audiometric changes at one or more frequencies after the second treatment course, and all but one patient reported auditory symptoms. No correlation was found between hearing loss and blood cisplatin pharmacokinetics. Platinum levels determined by inductively coupled plasma mass spectrometry were higher than total platinum levels calculated from cisplatin and monohydrated complex concentrations obtained by liquid chromatography analysis.<br />Conclusion: Ototoxicity was unacceptable despite amifostine treatment. Cisplatin pharmacokinetics during the first treatment course were not predictive of hearing loss. Amifostine caused a lowering of dose-normalized area under the concentration-time curve for cisplatin and monohydrated complex. Use of the unselective inductively coupled plasma mass spectrometry analysis leads to an overestimation of active drug. Selective analysis of cisplatin is especially important when evaluating cisplatin pharmacokinetics during chemoprotector treatment.
- Subjects :
- Adult
Aged
Amifostine adverse effects
Antineoplastic Agents administration & dosage
Antineoplastic Agents pharmacokinetics
Audiometry, Pure-Tone
Auditory Threshold drug effects
Cisplatin administration & dosage
Cisplatin pharmacokinetics
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Hearing Loss, Sensorineural blood
Hearing Loss, Sensorineural prevention & control
Humans
Male
Melanoma blood
Melanoma pathology
Metabolic Clearance Rate drug effects
Middle Aged
Neoplasm Staging
Neuroprotective Agents adverse effects
Prospective Studies
Skin Neoplasms blood
Skin Neoplasms pathology
Amifostine therapeutic use
Antineoplastic Agents toxicity
Cisplatin toxicity
Hearing Loss, Sensorineural chemically induced
Melanoma drug therapy
Neuroprotective Agents therapeutic use
Skin Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0023-852X
- Volume :
- 114
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- The Laryngoscope
- Publication Type :
- Academic Journal
- Accession number :
- 15475801
- Full Text :
- https://doi.org/10.1097/00005537-200409000-00030